{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039902","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.635096+00:00","generated_at":"2026-06-08T09:30:13.397107+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Matinas BioPharma reports Q3 net loss $6.1M; FDA supports MAT2203 Phase 3 with LPAD pathway","bullets":["Net loss of $6.1M ($0.03 per share) in Q3 2023 vs $5.5M in Q3 2022; no revenue vs $1.1M from BioNTech in prior year.","Cash $18.2M at Sep 30, 2023; runway into Q3 2024; seeking non-dilutive BARDA funding.","FDA agreed MAT2203 Phase 3 design for invasive aspergillosis with limited treatment options; acknowledged LPAD registration pathway.","FDA open to superiority composite endpoint to strengthen commercial positioning without increasing study size (<200 patients).","Patient with Candida krusei achieved complete clinical resolution after 2 weeks on MAT2203; new fusarium patient enrolled at Vanderbilt."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039902","json":"https://secwatch.observer/filing/0001493152-23-039902.json","markdown":"https://secwatch.observer/filing/0001493152-23-039902.md","text":"https://secwatch.observer/filing/0001493152-23-039902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223039902/0001493152-23-039902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223039902/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:30:13.397107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}